<!doctype html>
<html lang="en">
<head>
  <meta charset="utf-8" />
  <meta name="viewport" content="width=device-width, initial-scale=1" />
  <title>MDT Report</title>
  <style>
    :root {
      --border: #e5e7eb;
      --muted: #6b7280;
      --bg: #ffffff;
      --card: #ffffff;
      --soft: #f7f7f8;
      --accent: #2563eb;
    }
    body { font-family: -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif; margin: 24px; background: var(--bg); }
    h1 { font-size: 20px; margin: 0 0 12px 0; }
    h2 { font-size: 16px; margin: 0 0 10px 0; }
    h3 { font-size: 14px; margin: 10px 0 6px 0; }
    .meta { color: var(--muted); font-size: 13px; margin-bottom: 14px; }
    .cols { display: grid; grid-template-columns: 1fr 1fr; gap: 12px; }
    .card { border: 1px solid var(--border); border-radius: 12px; padding: 12px 14px; background: var(--card); }
    details { border: 1px solid var(--border); border-radius: 12px; padding: 10px 12px; background: var(--card); }
    summary { cursor: pointer; font-weight: 600; }
    pre { white-space: pre-wrap; word-wrap: break-word; background: var(--soft); padding: 12px; border-radius: 10px; overflow-x: auto; }
    .mono { font-family: ui-monospace, SFMono-Regular, Menlo, Monaco, Consolas, "Liberation Mono", "Courier New", monospace; }
    .mt { margin-top: 12px; }
    .hint { color: var(--muted); font-size: 12px; margin-top: 6px; }
    .warn { color: #b45309; font-weight: 600; }
    table.grid { width: 100%; border-collapse: collapse; font-size: 13px; }
    table.grid th, table.grid td { border: 1px solid var(--border); padding: 8px; vertical-align: top; }
    table.grid th { background: #f3f4f6; text-align: left; }
  </style>
</head>
<body>
  <h1>OMGs / MDT Report</h1>
  <div class="meta">
    <div><b>Timestamp</b>: 2026-01-18_01-06-20</div>
  </div>

  <div class="cols mt">
    <div class="card">
      <h2>Final MDT Output</h2>
      <pre>Final Assessment:
Postoperative bilateral tubo‑ovarian high‑grade serous carcinoma with peritoneal involvement and synchronous early-stage ER+/HER2‑ breast cancer; staging, BRCA/HRD status, labs, and imaging remain incomplete.

Core Treatment Strategy:
- Prioritize completion of integrated gyn-onc pathology report and formal FIGO staging, including documentation of residual disease and margins.
- Obtain baseline CBC, renal/hepatic function, performance status, and venous access assessment before starting any systemic therapy.
- Arrange dedicated postoperative pelvic CT/MRI, serial chest CT, and full PET/CT report review to define residual disease and lung nodule significance.
- Initiate standard adjuvant systemic therapy for advanced HGSC once workup complete; later coordinate appropriate maintenance based on BRCA/HRD.
- Coordinate breast MDT to finalize endocrine ± radiation sequencing around ovarian chemotherapy, ensuring margins/nodes confirmed on synoptic report.

Change Triggers:
- If imaging/pathology reveal unresected bulky disease or higher FIGO stage, escalate systemic intensity and consider multidisciplinary review of local options.
- If germline/somatic BRCA or HRD positive, prioritize PARP-inclusive maintenance approach once ovarian first-line chemotherapy completed.
- If chest CT shows progressive lung nodules or metastatic pattern, re-stage as systemic disease and adjust ovarian regimen and goals.
- If baseline labs or performance status are poor, delay/intensify supportive care and de-escalate or modify systemic treatment plan.
- If breast pathology reveals unexpected high-risk features (e.g., positive margins/nodes), re-balance timing/intensity of breast radiation/systemic therapy versus ovarian treatment.</pre>
    </div>
    <div class="card">
      <h2>Question (raw)</h2>
      <div class="hint">Original user question for observability (passed from main via args.question_raw).</div>
      <pre>卵巢恶性肿瘤：超声报告（2024.06.05）：右乳外下实质结节伴钙化(BI-RADS:4B) 双乳小叶增生；左乳实质结节(BI-RADS:3) 两侧腋下未见明显占位 两侧下肢静脉未见异常PET/CT：1.盆腔囊实性占位，与子宫及双侧附件关系密切，实性部分FDG代谢增高，MT可能；腹膜M；盆腔少量积液。 2.右乳外下象限致密影，FDG代谢增高，请结合穿刺活检。 3.双侧颈部淋巴结炎性增生；右下肺结节，未见FDG代谢增高，随访；左上肺陈旧灶；胆囊炎症可能。2024.06.06行盆腔肿块切除术（女性）+双附件切除术+盆底腹膜切除术+大网膜切除术+阑尾切除术+瘤体减灭术+复杂肠粘连松解术手术（盆腔肿块）低分化癌，倾向高级别浆液性癌，大小5*3*2cm，请待免疫组化辅助诊断。补充诊断1：补充报告: （盆腔肿块）高级别浆液性癌，大小5*3*2cm。【补充免疫组化结果】瘤细胞示：ER（部分+），PR（-），P53（-，突变型），WT1（+），Ki-67（+60%），HER2（0），HNF1B（-），NapsinA（-），P16（部分+），IMP3（+），PAX8（+）。; 补充报告医生：袁艺洮;　复诊医生：郑强;　补充报告日期：2024-06-17 ;（巨大盆块+双附件+全盆底腹膜+大网膜肿块）低分化癌，大小10×6×5.5cm，正行免疫组化辅助诊断。双侧卵巢及输卵管及盆底腹膜及大网膜均见癌累及。（大网膜）见癌累及。（右结肠旁沟肿瘤）见癌累及。（阑尾）慢性炎。右乳空心针穿刺;（右乳）浸润性癌，伴部分导管原位癌。术后复诊，尿管未拔，后续诊疗标本类型:右乳腺单纯切除术肿瘤所在位置:外下象限肿瘤大小:2*2*1.5 cm组织学类型:浸润性癌，非特殊类型，伴导管原位成分。组织学分级:Ⅱ级脉管侵犯:（-）乳头:（-）皮肤:（-）基底:（-）其余象限乳腺组织内上象限:（-）内下象限:（-）外上象限:（-）保乳手术切缘情况:上切缘:/下切缘:/内切缘:/外切缘:/表面:/基底:/淋巴结转移情况 :腋窝淋巴结(0/3)(转移数/淋巴结总数)淋巴结被膜外累犯(ENE)：/其他检查:/PTNM分期:pT1cN0Mx瘤细胞示：ER（+&gt;80％，强），PR（+&gt;80％，中-强），HER2（1+），Ki-67（+&lt;10％），AR（+&gt;80％，强），CD8（+&lt;10％），FOXC1（-），E-Cad（+），P120（膜+），CK5/6（-），P63（-），GATA3（+），TRPS1（+），GCDFP15（-）备注：本例ER、PR、HER2免疫组化均设置组织芯片对照，并行染色，染色结果符合预期。体格检查：右乳外下可见结节，约1.5cm，可推动，腋下及锁骨上（-）</pre>

      <details class="mt">
        <summary>Case (Structured JSON)</summary>
        <pre>{&quot;CASE_CORE&quot;:{&quot;ADJUVANT_TREATMENT&quot;:{&quot;cycles_or_courses&quot;:&quot;Unknown&quot;,&quot;given&quot;:&quot;Unknown&quot;,&quot;regimens&quot;:[]},&quot;BIOMARKERS&quot;:{&quot;AFP&quot;:&quot;Unknown&quot;,&quot;CA125&quot;:&quot;Unknown&quot;,&quot;HER2&quot;:&quot;0&quot;,&quot;MSI&quot;:&quot;Unknown&quot;,&quot;PDL1_CPS&quot;:&quot;Unknown&quot;,&quot;TMB&quot;:&quot;Unknown&quot;},&quot;BRCA1&quot;:&quot;Unknown&quot;,&quot;BRCA2&quot;:&quot;Unknown&quot;,&quot;CURRENT_STATUS&quot;:&quot;Postoperative; ureter not removed at postoperative follow-up&quot;,&quot;DIAGNOSIS&quot;:{&quot;components&quot;:[&quot;ovary&quot;,&quot;fallopian tube&quot;,&quot;pelvic peritoneum&quot;,&quot;omentum&quot;,&quot;right paracolic gutter tumor&quot;],&quot;histology&quot;:&quot;高级别浆液性癌&quot;,&quot;laterality&quot;:&quot;Bilateral&quot;,&quot;primary&quot;:&quot;卵巢恶性肿瘤&quot;,&quot;site&quot;:&quot;Pelvis/ovary&quot;},&quot;HRD&quot;:&quot;Unknown&quot;,&quot;INITIAL_TREATMENT&quot;:&quot;Yes&quot;,&quot;LINE_OF_THERAPY&quot;:[],&quot;MAINTENANCE&quot;:&quot;Unknown&quot;,&quot;MAINTENANCE_DETAIL&quot;:{&quot;end_date&quot;:&quot;Unknown&quot;,&quot;given&quot;:&quot;Unknown&quot;,&quot;regimens&quot;:[],&quot;start_date&quot;:&quot;Unknown&quot;},&quot;NEOADJUVANT&quot;:&quot;Unknown&quot;,&quot;PFI_days&quot;:&quot;Unknown&quot;,&quot;PLATINUM_HISTORY&quot;:[],&quot;PLATINUM_PFI_CURRENT&quot;:&quot;Unknown&quot;,&quot;PLATINUM_STATUS&quot;:&quot;Unknown&quot;,&quot;PLATINUM_STATUS_CURRENT&quot;:&quot;Unknown&quot;,&quot;RELAPSE&quot;:&quot;No&quot;,&quot;RELAPSE_DATE&quot;:{&quot;date&quot;:&quot;Unknown&quot;,&quot;evidence&quot;:&quot;&quot;,&quot;type&quot;:&quot;Unknown&quot;},&quot;SCENE&quot;:&quot;Frontline_PDS_or_NACT_IDS&quot;,&quot;STAGE&quot;:{&quot;stage_basis&quot;:&quot;Unknown&quot;,&quot;stage_system&quot;:&quot;Unknown&quot;,&quot;stage_text&quot;:&quot;Unknown&quot;},&quot;SURGERY_DONE&quot;:{&quot;date&quot;:&quot;2024-06-06&quot;,&quot;performed&quot;:&quot;Yes&quot;,&quot;procedure&quot;:&quot;Pelvic mass resection; bilateral salpingo-oophorectomy; pelvic peritoneum resection; omentectomy; appendectomy; tumor debulking; complex adhesiolysis&quot;},&quot;TIMELINE&quot;:{&quot;constraints&quot;:{&quot;max_events&quot;:30,&quot;min_events&quot;:3,&quot;must_include&quot;:[&quot;first diagnostic imaging or pathology confirmation (if available)&quot;],&quot;ordering_rules&quot;:{&quot;prioritize_last_event&quot;:true}},&quot;events&quot;:[{&quot;date&quot;:&quot;2024-06-05&quot;,&quot;description&quot;:&quot;Ultrasound: right breast outer-lower solid nodule with calcification (BI-RADS 4B); left breast solid nodule BI-RADS 3; bilateral axilla no obvious mass; lower limb veins no abnormality&quot;,&quot;event_type&quot;:&quot;Imaging&quot;,&quot;key_result&quot;:&quot;Right breast nodule BI-RADS 4B&quot;,&quot;regimen_or_test&quot;:&quot;Ultrasound&quot;},{&quot;date&quot;:&quot;Unknown&quot;,&quot;description&quot;:&quot;FDG-PET/CT: pelvic cystic-solid mass with FDG-avid solid component; possible malignancy and peritoneal metastasis; small pelvic effusion; FDG-avid right breast outer-lower density, recommend biopsy; other findings&quot;,&quot;event_type&quot;:&quot;Imaging&quot;,&quot;key_result&quot;:&quot;Pelvic mass FDG-avid; right breast FDG-avid&quot;,&quot;regimen_or_test&quot;:&quot;FDG-PET/CT&quot;},{&quot;date&quot;:&quot;2024-06-06&quot;,&quot;description&quot;:&quot;Pelvic mass resection + bilateral adnexectomy + pelvic peritoneum resection + omentectomy + appendectomy + debulking + complex adhesiolysis&quot;,&quot;event_type&quot;:&quot;Surgery&quot;,&quot;key_result&quot;:&quot;Operative resection of pelvic mass and multiple specimens obtained&quot;,&quot;regimen_or_test&quot;:&quot;Surgery&quot;},{&quot;date&quot;:&quot;2024-06-06&quot;,&quot;description&quot;:&quot;Pelvic mass pathology initial: low-differentiation carcinoma, tending to high-grade serous carcinoma, size 5*3*2 cm; awaiting IHC&quot;,&quot;event_type&quot;:&quot;Pathology&quot;,&quot;key_result&quot;:&quot;Low-differentiation carcinoma, favor high-grade serous&quot;,&quot;regimen_or_test&quot;:&quot;Histopathology&quot;},{&quot;date&quot;:&quot;2024-06-17&quot;,&quot;description&quot;:&quot;Supplementary pathology: high-grade serous carcinoma of pelvic mass, size 5*3*2 cm; immunohistochemistry provided&quot;,&quot;event_type&quot;:&quot;Pathology&quot;,&quot;key_result&quot;:&quot;Diagnosis: 高级别浆液性癌; IHC results documented&quot;,&quot;regimen_or_test&quot;:&quot;Supplementary pathology and IHC&quot;},{&quot;date&quot;:&quot;Unknown&quot;,&quot;description&quot;:&quot;Right breast core biopsy: invasive carcinoma with ductal carcinoma in situ component&quot;,&quot;event_type&quot;:&quot;Pathology&quot;,&quot;key_result&quot;:&quot;Right breast invasive carcinoma with DCIS&quot;,&quot;regimen_or_test&quot;:&quot;Core needle biopsy&quot;},{&quot;date&quot;:&quot;Unknown&quot;,&quot;description&quot;:&quot;Right breast simple mastectomy specimen: invasive carcinoma, NST, with DCIS, tumor 2*2*1.5 cm, pT1cN0Mx; IHC results documented&quot;,&quot;event_type&quot;:&quot;Pathology&quot;,&quot;key_result&quot;:&quot;pT1cN0Mx; ER/PR positive; HER2 1+&quot;,&quot;regimen_or_test&quot;:&quot;Mastectomy pathology&quot;}]},&quot;VISIT_DATE&quot;:&quot;2024-07-17&quot;,&quot;first_relapse_date&quot;:&quot;Unknown&quot;,&quot;last_platinum_end_date&quot;:&quot;Unknown&quot;},&quot;LAB_TRENDS&quot;:{&quot;labs&quot;:[],&quot;milestones&quot;:[{&quot;date&quot;:&quot;2024-06-06&quot;,&quot;description&quot;:&quot;Pelvic mass resection and multiple procedures&quot;,&quot;title&quot;:&quot;Surgery&quot;,&quot;type&quot;:&quot;Surgery&quot;}]},&quot;MED_ONC&quot;:{&quot;current_regimen&quot;:{&quot;cycle_info&quot;:&quot;Unknown&quot;,&quot;last_admin_date&quot;:&quot;Unknown&quot;,&quot;name&quot;:&quot;Unknown&quot;},&quot;genetic_testing&quot;:{&quot;germline&quot;:[],&quot;somatic&quot;:[]},&quot;monitoring_points&quot;:[],&quot;planned_next_regimen&quot;:&quot;Unknown&quot;,&quot;prior_systemic_therapies&quot;:[]},&quot;NUC_MED&quot;:{&quot;studies&quot;:[]},&quot;PATHOLOGY&quot;:{&quot;specimens&quot;:[{&quot;components&quot;:[&quot;pelvic mass&quot;],&quot;date&quot;:&quot;2024-06-06&quot;,&quot;diagnosis&quot;:&quot;低分化癌，倾向高级别浆液性癌&quot;,&quot;grade&quot;:&quot;Low differentiated&quot;,&quot;ihc&quot;:[{&quot;marker&quot;:&quot;ER&quot;,&quot;result&quot;:&quot;部分+&quot;},{&quot;marker&quot;:&quot;PR&quot;,&quot;result&quot;:&quot;-&quot;},{&quot;marker&quot;:&quot;P53&quot;,&quot;result&quot;:&quot;-，突变型&quot;},{&quot;marker&quot;:&quot;WT1&quot;,&quot;result&quot;:&quot;+&quot;},{&quot;marker&quot;:&quot;Ki-67&quot;,&quot;result&quot;:&quot;+60%&quot;},{&quot;marker&quot;:&quot;HER2&quot;,&quot;result&quot;:&quot;0&quot;},{&quot;marker&quot;:&quot;HNF1B&quot;,&quot;result&quot;:&quot;-&quot;},{&quot;marker&quot;:&quot;NapsinA&quot;,&quot;result&quot;:&quot;-&quot;},{&quot;marker&quot;:&quot;P16&quot;,&quot;result&quot;:&quot;部分+&quot;},{&quot;marker&quot;:&quot;IMP3&quot;,&quot;result&quot;:&quot;+&quot;},{&quot;marker&quot;:&quot;PAX8&quot;,&quot;result&quot;:&quot;+&quot;}],&quot;involvement_sites&quot;:[&quot;bilateral ovaries&quot;,&quot;fallopian tubes&quot;,&quot;pelvic peritoneum&quot;,&quot;omentum&quot;],&quot;laterality&quot;:&quot;Unknown&quot;,&quot;molecular&quot;:[],&quot;raw_text&quot;:&quot;2024.06.06行盆腔肿块切除术...（盆腔肿块）低分化癌，倾向高级别浆液性癌，大小5*3*2cm，请待免疫组化辅助诊断。&quot;,&quot;sample_type&quot;:&quot;Resection&quot;,&quot;site&quot;:&quot;Pelvic mass&quot;,&quot;tumor_size&quot;:&quot;5*3*2cm&quot;,&quot;uncertainty_or_missing&quot;:[&quot;Initial report: awaiting IHC&quot;]},{&quot;components&quot;:[&quot;pelvic mass&quot;],&quot;date&quot;:&quot;2024-06-17&quot;,&quot;diagnosis&quot;:&quot;高级别浆液性癌&quot;,&quot;grade&quot;:&quot;Unknown&quot;,&quot;ihc&quot;:[{&quot;marker&quot;:&quot;ER&quot;,&quot;result&quot;:&quot;部分+&quot;},{&quot;marker&quot;:&quot;PR&quot;,&quot;result&quot;:&quot;-&quot;},{&quot;marker&quot;:&quot;P53&quot;,&quot;result&quot;:&quot;-，突变型&quot;},{&quot;marker&quot;:&quot;WT1&quot;,&quot;result&quot;:&quot;+&quot;},{&quot;marker&quot;:&quot;Ki-67&quot;,&quot;result&quot;:&quot;+60%&quot;},{&quot;marker&quot;:&quot;HER2&quot;,&quot;result&quot;:&quot;0&quot;},{&quot;marker&quot;:&quot;HNF1B&quot;,&quot;result&quot;:&quot;-&quot;},{&quot;marker&quot;:&quot;NapsinA&quot;,&quot;result&quot;:&quot;-&quot;},{&quot;marker&quot;:&quot;P16&quot;,&quot;result&quot;:&quot;部分+&quot;},{&quot;marker&quot;:&quot;IMP3&quot;,&quot;result&quot;:&quot;+&quot;},{&quot;marker&quot;:&quot;PAX8&quot;,&quot;result&quot;:&quot;+&quot;}],&quot;involvement_sites&quot;:[&quot;bilateral ovaries&quot;,&quot;fallopian tubes&quot;,&quot;pelvic peritoneum&quot;,&quot;omentum&quot;],&quot;laterality&quot;:&quot;Unknown&quot;,&quot;molecular&quot;:[],&quot;raw_text&quot;:&quot;补充报告日期：2024-06-17；（盆腔肿块）高级别浆液性癌，大小5*3*2cm。【补充免疫组化结果】瘤细胞示：ER（部分+），PR（-），P53（-，突变型），WT1（+），Ki-67（+60%），HER2（0），HNF1B（-），NapsinA（-），P16（部分+），IMP3（+），PAX8（+）。&quot;,&quot;sample_type&quot;:&quot;Supplementary pathology with IHC&quot;,&quot;site&quot;:&quot;Pelvic mass (supplement)&quot;,&quot;tumor_size&quot;:&quot;5*3*2cm&quot;,&quot;uncertainty_or_missing&quot;:[]},{&quot;components&quot;:[&quot;巨大盆块&quot;,&quot;omentum&quot;],&quot;date&quot;:&quot;Unknown&quot;,&quot;diagnosis&quot;:&quot;低分化癌&quot;,&quot;grade&quot;:&quot;Low differentiated&quot;,&quot;ihc&quot;:[],&quot;involvement_sites&quot;:[&quot;bilateral ovaries&quot;,&quot;fallopian tubes&quot;,&quot;pelvic peritoneum&quot;,&quot;omentum&quot;,&quot;right paracolic gutter tumor&quot;],&quot;laterality&quot;:&quot;Unknown&quot;,&quot;molecular&quot;:[],&quot;raw_text&quot;:&quot;（巨大盆块+双附件+全盆底腹膜+大网膜肿块）低分化癌，大小10×6×5.5cm。双侧卵巢及输卵管及盆底腹膜及大网膜均见癌累及。（大网膜）见癌累及。（右结肠旁沟肿瘤）见癌累及。（阑尾）慢性炎。&quot;,&quot;sample_type&quot;:&quot;Resection&quot;,&quot;site&quot;:&quot;Large pelvic mass / omental mass&quot;,&quot;tumor_size&quot;:&quot;10×6×5.5cm&quot;,&quot;uncertainty_or_missing&quot;:[]},{&quot;components&quot;:[&quot;breast core biopsy&quot;],&quot;date&quot;:&quot;Unknown&quot;,&quot;diagnosis&quot;:&quot;浸润性癌，伴部分导管原位癌&quot;,&quot;grade&quot;:&quot;Unknown&quot;,&quot;ihc&quot;:[],&quot;involvement_sites&quot;:[],&quot;laterality&quot;:&quot;Right&quot;,&quot;molecular&quot;:[],&quot;raw_text&quot;:&quot;右乳空心针穿刺;（右乳）浸润性癌，伴部分导管原位癌。&quot;,&quot;sample_type&quot;:&quot;Core needle biopsy&quot;,&quot;site&quot;:&quot;Right breast core biopsy&quot;,&quot;tumor_size&quot;:&quot;Unknown&quot;,&quot;uncertainty_or_missing&quot;:[]},{&quot;components&quot;:[&quot;breast&quot;],&quot;date&quot;:&quot;Unknown&quot;,&quot;diagnosis&quot;:&quot;Invasive carcinoma, non-special type, with DCIS component&quot;,&quot;grade&quot;:&quot;Ⅱ级&quot;,&quot;ihc&quot;:[{&quot;marker&quot;:&quot;ER&quot;,&quot;result&quot;:&quot;+&gt;80％，强&quot;},{&quot;marker&quot;:&quot;PR&quot;,&quot;result&quot;:&quot;+&gt;80％，中-强&quot;},{&quot;marker&quot;:&quot;HER2&quot;,&quot;result&quot;:&quot;1+&quot;},{&quot;marker&quot;:&quot;Ki-67&quot;,&quot;result&quot;:&quot;+&lt;10％&quot;},{&quot;marker&quot;:&quot;AR&quot;,&quot;result&quot;:&quot;+&gt;80％，强&quot;},{&quot;marker&quot;:&quot;CD8&quot;,&quot;result&quot;:&quot;+&lt;10％&quot;},{&quot;marker&quot;:&quot;FOXC1&quot;,&quot;result&quot;:&quot;-&quot;},{&quot;marker&quot;:&quot;E-Cad&quot;,&quot;result&quot;:&quot;+&quot;},{&quot;marker&quot;:&quot;P120&quot;,&quot;result&quot;:&quot;膜+&quot;},{&quot;marker&quot;:&quot;CK5/6&quot;,&quot;result&quot;:&quot;-&quot;},{&quot;marker&quot;:&quot;P63&quot;,&quot;result&quot;:&quot;-&quot;},{&quot;marker&quot;:&quot;GATA3&quot;,&quot;result&quot;:&quot;+&quot;},{&quot;marker&quot;:&quot;TRPS1&quot;,&quot;result&quot;:&quot;+&quot;},{&quot;marker&quot;:&quot;GCDFP15&quot;,&quot;result&quot;:&quot;-&quot;}],&quot;involvement_sites&quot;:[&quot;axillary lymph nodes (0/3)&quot;],&quot;laterality&quot;:&quot;Right&quot;,&quot;molecular&quot;:[],&quot;raw_text&quot;:&quot;右乳腺单纯切除术...组织学类型:浸润性癌，非特殊类型，伴导管原位成分。组织学分级:Ⅱ级...腋窝淋巴结(0/3)...PTNM分期:pT1cN0Mx。瘤细胞示：ER（+&gt;80％，强），PR（+&gt;80％，中-强），HER2（1+），Ki-67（+&lt;10％），AR（+&gt;80％，强）等。&quot;,&quot;sample_type&quot;:&quot;Mastectomy&quot;,&quot;site&quot;:&quot;Right breast mastectomy&quot;,&quot;tumor_size&quot;:&quot;2*2*1.5 cm&quot;,&quot;uncertainty_or_missing&quot;:[]}]},&quot;RADIOLOGY&quot;:{&quot;next_imaging_plan&quot;:{&quot;modality&quot;:&quot;Unknown&quot;,&quot;timing&quot;:&quot;Unknown&quot;},&quot;studies&quot;:[{&quot;anatomic_sites&quot;:[&quot;breasts&quot;],&quot;date&quot;:&quot;2024-06-05&quot;,&quot;findings&quot;:[&quot;Right outer-lower breast solid nodule with calcification (BI-RADS 4B)&quot;,&quot;Bilateral lobular hyperplasia&quot;,&quot;Left breast solid nodule (BI-RADS 3)&quot;,&quot;No obvious axillary masses bilaterally&quot;,&quot;Lower limb veins unremarkable&quot;],&quot;impression&quot;:&quot;Right breast outer-lower solid nodule with calcification (BI-RADS 4B); left breast nodule BI-RADS 3&quot;,&quot;modality&quot;:&quot;US&quot;,&quot;trend_vs_prior&quot;:&quot;Unknown&quot;},{&quot;anatomic_sites&quot;:[&quot;pelvis&quot;,&quot;breasts&quot;,&quot;neck lymph nodes&quot;,&quot;lungs&quot;,&quot;gallbladder&quot;],&quot;date&quot;:&quot;Unknown&quot;,&quot;findings&quot;:[&quot;Pelvic cystic-solid mass closely related to uterus and adnexa; solid component FDG-avid&quot;,&quot;Possible malignant tumor in pelvis; peritoneal metastasis; small pelvic effusion&quot;,&quot;Right breast outer-lower dense shadow FDG-avid, recommend biopsy&quot;,&quot;Bilateral neck lymph nodes inflammatory hyperplasia&quot;,&quot;Right lower lung nodule without FDG uptake (follow-up)&quot;,&quot;Left upper lung chronic focus&quot;,&quot;Possible cholecystitis&quot;],&quot;impression&quot;:&quot;FDG-avid pelvic mass suggesting malignancy with peritoneal involvement; FDG-avid right breast lesion, biopsy recommended&quot;,&quot;modality&quot;:&quot;Other&quot;,&quot;trend_vs_prior&quot;:&quot;Unknown&quot;}]},&quot;TIMELINE&quot;:{&quot;constraints&quot;:{&quot;max_events&quot;:30,&quot;min_events&quot;:3,&quot;must_include&quot;:[&quot;first diagnostic imaging or pathology confirmation (if available)&quot;],&quot;ordering_rules&quot;:{&quot;prioritize_last_event&quot;:true}},&quot;events&quot;:[{&quot;date&quot;:&quot;2024-06-05&quot;,&quot;description&quot;:&quot;Ultrasound: right breast outer-lower solid nodule with calcification (BI-RADS 4B); left breast solid nodule BI-RADS 3; bilateral axilla no obvious mass; lower limb veins no abnormality&quot;,&quot;event_type&quot;:&quot;Imaging&quot;,&quot;key_result&quot;:&quot;Right breast nodule BI-RADS 4B&quot;,&quot;regimen_or_test&quot;:&quot;Ultrasound&quot;},{&quot;date&quot;:&quot;Unknown&quot;,&quot;description&quot;:&quot;FDG-PET/CT: pelvic cystic-solid mass with FDG-avid solid component; possible malignancy and peritoneal metastasis; small pelvic effusion; FDG-avid right breast outer-lower density, recommend biopsy; other findings&quot;,&quot;event_type&quot;:&quot;Imaging&quot;,&quot;key_result&quot;:&quot;Pelvic mass FDG-avid; right breast FDG-avid&quot;,&quot;regimen_or_test&quot;:&quot;FDG-PET/CT&quot;},{&quot;date&quot;:&quot;2024-06-06&quot;,&quot;description&quot;:&quot;Pelvic mass resection + bilateral adnexectomy + pelvic peritoneum resection + omentectomy + appendectomy + debulking + complex adhesiolysis&quot;,&quot;event_type&quot;:&quot;Surgery&quot;,&quot;key_result&quot;:&quot;Operative resection of pelvic mass and multiple specimens obtained&quot;,&quot;regimen_or_test&quot;:&quot;Surgery&quot;},{&quot;date&quot;:&quot;2024-06-06&quot;,&quot;description&quot;:&quot;Pelvic mass pathology initial: low-differentiation carcinoma, tending to high-grade serous carcinoma, size 5*3*2 cm; awaiting IHC&quot;,&quot;event_type&quot;:&quot;Pathology&quot;,&quot;key_result&quot;:&quot;Low-differentiation carcinoma, favor high-grade serous&quot;,&quot;regimen_or_test&quot;:&quot;Histopathology&quot;},{&quot;date&quot;:&quot;2024-06-17&quot;,&quot;description&quot;:&quot;Supplementary pathology: high-grade serous carcinoma of pelvic mass, size 5*3*2 cm; immunohistochemistry provided&quot;,&quot;event_type&quot;:&quot;Pathology&quot;,&quot;key_result&quot;:&quot;Diagnosis: 高级别浆液性癌; IHC results documented&quot;,&quot;regimen_or_test&quot;:&quot;Supplementary pathology and IHC&quot;},{&quot;date&quot;:&quot;Unknown&quot;,&quot;description&quot;:&quot;Right breast core biopsy: invasive carcinoma with ductal carcinoma in situ component&quot;,&quot;event_type&quot;:&quot;Pathology&quot;,&quot;key_result&quot;:&quot;Right breast invasive carcinoma with DCIS&quot;,&quot;regimen_or_test&quot;:&quot;Core needle biopsy&quot;},{&quot;date&quot;:&quot;Unknown&quot;,&quot;description&quot;:&quot;Right breast simple mastectomy specimen: invasive carcinoma, NST, with DCIS, tumor 2*2*1.5 cm, pT1cN0Mx; IHC results documented&quot;,&quot;event_type&quot;:&quot;Pathology&quot;,&quot;key_result&quot;:&quot;pT1cN0Mx; ER/PR positive; HER2 1+&quot;,&quot;regimen_or_test&quot;:&quot;Mastectomy pathology&quot;}]}}</pre>
      </details>
    </div>
  </div>

  <details class="mt" open>
    <summary>Expert Debate (Round × Turn)</summary>
    <table class='grid'><tr><th>Round</th><th>Turn</th><th>From</th><th>To</th><th>Message</th></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 1</td><td class='mono'>chair</td><td class='mono'>oncologist</td><td>Before fixing the frontline ovarian regimen and breast adjuvant sequencing, we must know FIGO stage, residual disease status, CA125 baseline/trend, performance status, and current organ function; please confirm whether these can be obtained and whether ovarian chemotherapy start will precede or overlap with breast endocrine/radiation plans.</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 1</td><td class='mono'>chair</td><td class='mono'>radiologist</td><td>Key imaging gaps remain: dedicated postoperative pelvic CT/MRI, full PET/CT report with distant disease assessment, and a plan for short‑interval follow‑up of the left BI‑RADS 3 breast lesion and indeterminate lung nodules; can you outline the needed studies and suggested timing?</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 1</td><td class='mono'>chair</td><td class='mono'>pathologist</td><td>To finalize staging and maintenance strategy, we need an integrated report confirming all peritoneal/omental/right paracolic lesions as high‑grade serous carcinoma, FIGO stage assignment, and detailed fallopian tube examination including any STIC; can you provide or update this?</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 1</td><td class='mono'>chair</td><td class='mono'>nuclear</td><td>The timeline references a PET/CT but we lack the formal report with SUVs and whole‑body staging details; please confirm whether any extra‑pelvic metastatic disease was identified that could upstage the ovarian cancer or alter systemic therapy intent.</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 1</td><td class='mono'>oncologist</td><td class='mono'>chair</td><td>Before finalizing adjuvant systemic therapy, we urgently need operative note, FIGO stage, residual disease status, baseline CA125, and organ-function labs to safely plan intensity and sequencing with breast treatment.</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 1</td><td class='mono'>radiologist</td><td class='mono'>oncologist</td><td>No dedicated postoperative pelvic CT/MRI or formal PET/CT report with measurable lesions and distant staging are available; updated cross‑sectional imaging is needed now for accurate FIGO staging, baseline disease documentation, and lung nodule assessment.</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 1</td><td class='mono'>pathologist</td><td class='mono'>chair</td><td>Final integrated pathology for the pelvic ‘poorly differentiated carcinoma’ vs ‘high‑grade serous carcinoma’ (single primary, FIGO stage, STIC assessment) is still missing and is critical for accurate staging and systemic planning.</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 1</td><td class='mono'>nuclear</td><td class='mono'>oncologist</td><td>Full PET/CT report (SUVs, nodal/distant disease, lung nodules characterization) is missing and essential to confirm current staging and recurrence suspicion.</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 1</td><td class='mono'>nuclear</td><td class='mono'>radiologist</td><td>Please provide the complete PET/CT report including detailed pelvic/peritoneal disease mapping, breast findings, and description of indeterminate lung nodules.</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 2</td><td class='mono'>chair</td><td class='mono'>oncologist</td><td>Before confirming adjuvant sequencing, we need operative notes, residual disease status, baseline CA125, and updated labs/performance status for systemic planning.</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 2</td><td class='mono'>chair</td><td class='mono'>radiologist</td><td>Please arrange a dedicated postoperative pelvic CT/MRI and serial chest CT to clarify FIGO stage, document residual disease, and characterize lung nodules.</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 2</td><td class='mono'>chair</td><td class='mono'>pathologist</td><td>We need an integrated final report clarifying whether all pelvic/peritoneal lesions represent a single high‑grade serous primary, with FIGO stage and STIC assessment.</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 2</td><td class='mono'>chair</td><td class='mono'>nuclear</td><td>Kindly provide the complete PET/CT report (SUVs, nodal/distant disease, detailed pelvic mapping, lung nodules) to finalize staging and baseline disease documentation.</td></tr><tr><td class='mono'>Round 2</td><td class='mono'>Turn 1</td><td class='mono'>chair</td><td class='mono'>oncologist</td><td>Before finalizing adjuvant sequencing, we must obtain FIGO stage, residual status, baseline CA125, performance status, and organ-function labs; also please initiate/confirm germline and somatic BRCA/HRD testing and propose a coordinated timetable with breast endocrine/radiation plans.</td></tr><tr><td class='mono'>Round 2</td><td class='mono'>Turn 1</td><td class='mono'>chair</td><td class='mono'>radiologist</td><td>Please arrange and formally report a dedicated postoperative pelvic CT/MRI and a staging chest CT (or PET/CT addendum) with explicit description of residual peritoneal disease and characterization/follow‑up plan for lung nodules and the left breast lesion.</td></tr><tr><td class='mono'>Round 2</td><td class='mono'>Turn 1</td><td class='mono'>chair</td><td class='mono'>pathologist</td><td>We need an integrated gyn-onc pathology summary assigning FIGO stage, confirming a single high-grade serous tubo-ovarian primary with documentation of all involved sites and STIC assessment, plus a synoptic breast report confirming margins and nodal status.</td></tr><tr><td class='mono'>Round 2</td><td class='mono'>Turn 1</td><td class='mono'>chair</td><td class='mono'>nuclear</td><td>Kindly provide/clarify the full preoperative PET/CT report with SUVs, nodal/distant disease mapping, and any recommendation on follow-up imaging to help us interpret lung and extra-pelvic findings in current staging.</td></tr><tr><td class='mono'>Round 2</td><td class='mono'>Turn 1</td><td class='mono'>pathologist</td><td class='mono'>chair</td><td>The ovarian pathology remains non‑integrated across multiple specimens; we still lack a single report assigning FIGO stage and STIC status, which is critical to finalize staging and systemic planning today.</td></tr><tr><td class='mono'>Round 2</td><td class='mono'>Turn 2</td><td class='mono'>chair</td><td class='mono'>oncologist</td><td>We cannot safely finalize systemic intensity or maintenance without integrated FIGO staging, residual status, CA125 baseline, organ function, and BRCA/HRD results—please outline a provisional adjuvant framework and timing assumptions contingent on these pending data.</td></tr><tr><td class='mono'>Round 2</td><td class='mono'>Turn 2</td><td class='mono'>chair</td><td class='mono'>radiologist</td><td>We need a dedicated postoperative pelvic CT/MRI and serial chest CT protocol (timing and technique) to document residual peritoneal disease and characterize the small lung nodules for accurate staging and follow-up planning.</td></tr><tr><td class='mono'>Round 2</td><td class='mono'>Turn 2</td><td class='mono'>chair</td><td class='mono'>pathologist</td><td>Please prioritize an integrated gyn-onc report that merges all pelvic/peritoneal specimens into a single FIGO stage assignment with confirmation of primary site and STIC assessment, plus a synoptic breast report confirming final margins and nodes, as this directly drives both ovarian and breast adjuvant decisions.</td></tr><tr><td class='mono'>Round 2</td><td class='mono'>Turn 2</td><td class='mono'>chair</td><td class='mono'>nuclear</td><td>We still require the full preoperative PET/CT with SUVs and a clear map of nodal and distant findings, including interpretation of lung nodules and any suggested follow-up schedule, to reconcile metabolic disease extent with planned anatomic imaging and systemic therapy.</td></tr></table>
    <div class="hint">Only includes messages that were actually emitted (non-empty).</div>
  </details>

  <details class="mt">
    <summary>Initial Expert Opinions (raw)</summary>
    <pre>{
  &quot;chair&quot;: &quot;- Postoperative high-grade serous ovarian carcinoma with peritoneal involvement: likely advanced stage; assume need for adjuvant systemic therapy unless contraindicated.  \n- Clarify staging and residual disease: operative note, final stage assignment, residual tumor status, postoperative imaging, and CA125 trend are urgently needed.  \n- Germline and somatic testing (BRCA1/2, HRD panel) should be sent now to guide future maintenance and family counseling.  \n- Right breast ER/PR+ early cancer is resected; coordinate adjuvant breast plan with ovarian therapy to avoid overlapping toxicities.  \n- Confirm current performance status, comorbidities, venous access, and patient preferences before finalizing systemic therapy intensity and sequencing.&quot;,
  &quot;oncologist&quot;: &quot;- High‑grade serous carcinoma involving ovary/fallopian tube/peritoneum post extensive cytoreductive surgery; adjuvant systemic therapy is indicated, intent curative.  \n\n- FIGO stage, residual disease status, and operative/pathology details are unknown/need update for adjuvant regimen intensity decision.  \n\n- No prior systemic therapy recorded; first‑line postoperative systemic treatment planning required, maintenance strategy currently unknown/needs definition.  \n\n- BRCA1/2 and homologous‑recombination status germline/somatic unknown/needs testing to guide future maintenance and relapse strategies.  \n\n- Current organ function, CA‑125 trend, performance status, and postoperative recovery/toxicities are unknown/need updated labs and clinical assessment.&quot;,
  &quot;radiologist&quot;: &quot;- FDG-avid pelvic cystic-solid mass with peritoneal nodularity and small effusion, imaging pattern suspicious for pelvic malignancy with peritoneal spread [@IMAGING_STUDIES|Unknown].  \n\n- Right outer-lower breast solid nodule with calcification, BI-RADS 4B on ultrasound, correlates with FDG-avid lesion; biopsy correlation needed [@IMAGING_STUDIES|2024-06-05; @IMAGING_STUDIES|Unknown].  \n\n- Left breast solid nodule categorized BI-RADS 3 on ultrasound; short-interval imaging follow-up recommended, no FDG data provided [@IMAGING_STUDIES|2024-06-05].  \n\n- Right lower lung non–FDG-avid nodule and left upper lung chronic focus; require CT chest measurements and interval comparison for characterization [@IMAGING_STUDIES|Unknown].  \n\n- Missing: dedicated pelvic MRI/CT for local staging and measurability; prior imaging for trend; pathology correlation for pelvic and breast lesions.&quot;,
  &quot;pathologist&quot;: &quot;- Pelvic tumor: high‑grade serous carcinoma involving ovaries, tubes, pelvic peritoneum, omentum, right paracolic gutter [@HISTOLOGY_AND_IHC.2|2024-06-17].  \n- Morphology/IHC (WT1+, PAX8+, aberrant p53, high Ki‑67) are typical for tubo‑ovarian high‑grade serous carcinoma.  \n- Pelvic/omental specimen labeled “poorly differentiated carcinoma” should be unified under high‑grade serous carcinoma; same disease assumed [@HISTOLOGY_AND_IHC.3|unknown].  \n- Separate right breast carcinoma: ER/PR/AR‑positive, HER2‑negative, low Ki‑67, pT1cN0, distinct primary [@HISTOLOGY_AND_IHC.5|unknown].  \n- Missing/needs update: FIGO stage; detailed fallopian tube examination (STIC?); germline/somatic BRCA/HRR status; CA125 and MSI/TMB/PD‑L1.&quot;,
  &quot;nuclear&quot;: &quot;- Prior PET suggests FDG-avid pelvic mass with peritoneal involvement, raising suspicion for advanced intra-abdominal malignancy and possible upstaging [@IMAGING_CONTEXT|Unknown].  \n- FDG-avid right breast lesion concerning for primary or metastatic focus; tissue diagnosis is essential for clarification [@IMAGING_CONTEXT|Unknown].  \n- Left breast BI-RADS 3 lesion appears low suspicion, but lacks metabolic characterization on PET/CT [@IMAGING_CONTEXT|2024-06-05].  \n- No formal PET/CT report is available for detailed lesion SUV, distribution, or nodal status—full report upload needed.  \n- Current staging and recurrence assessment remain uncertain; require updated whole-body PET/CT report dated for this visit or later.&quot;
}</pre>
  </details>

  <details class="mt">
    <summary>Final Refined Plans (per round, raw)</summary>
    <pre>{
  &quot;Round 1&quot;: {
    &quot;chair&quot;: &quot;- Complete staging: obtain operative note, integrated pathology with FIGO stage/STIC, residual status, and full PET/CT plus pelvic CT/MRI and chest CT (all currently unknown).  \n- Establish systemic readiness: document CA125 baseline/trend, organ function labs, ECOG status, postoperative complications, and venous access to plan curative‑intent adjuvant ovarian chemotherapy (all unknown).  \n- Molecular/family: expedite germline and somatic BRCA1/2 and HRD/HRR testing; arrange genetic counseling for patient and at‑risk relatives once results available.  \n- Breast coordination: confirm final adjuvant breast plan (endocrine ± radiation/systemic), then sequence to avoid overlapping toxicities while not delaying ovarian chemotherapy.  \n- Surveillance strategy: clarify lung nodule significance with serial chest CT, and ensure planned imaging follow‑up of left breast BI‑RADS 3 lesion.&quot;,
    &quot;oncologist&quot;: &quot;- Proceed with first‑line adjuvant systemic therapy for high‑grade serous tubo‑ovarian carcinoma, intent curative; regimen choice pending staging/fitness details (unknown/needs update).  \n\n- Obtain operative note, integrated pathology with FIGO stage/STIC, and residual disease status to calibrate adjuvant intensity and maintenance strategy (unknown/needs update).  \n\n- Update baseline CA125, CBC, renal/hepatic function, and performance status to confirm treatment eligibility and dosing (unknown/needs update).  \n\n- Coordinate with breast team to initiate adjuvant endocrine ± local breast therapy, sequencing around ovarian chemotherapy once systemic plan defined (unknown/needs update).  \n\n- Expedite germline and somatic BRCA/HRD testing and complete postoperative pelvic and chest imaging plus full PET/CT report for staging and surveillance (unknown/needs update).&quot;,
    &quot;radiologist&quot;: &quot;- Await dedicated postoperative pelvic CT/MRI and serial chest CT to define FIGO stage, residual disease, and lung nodules; currently unknown/needs update.  \n\n- Obtain full PET/CT report with SUVs, detailed pelvic/peritoneal mapping, nodal/distant disease, and lung nodule description; currently unknown/needs update.  \n\n- Integrate final pathology clarifying single high‑grade serous primary vs multiple sites, FIGO stage, and STIC status; currently unknown/needs update.  \n\n- Use updated cross‑sectional and PET/CT imaging to establish measurable postoperative baseline for ovarian cancer surveillance; currently unknown/needs update.  \n\n- Maintain short‑interval imaging follow‑up plan for left breast BI‑RADS 3 lesion and chest nodules once prior reports available; currently unknown/needs update.&quot;,
    &quot;pathologist&quot;: &quot;- Integrate pelvic/peritoneal specimens into one report confirming single high‑grade serous tubo‑ovarian carcinoma and FIGO stage [@HISTOLOGY_AND_IHC.2|2024-06-17].  \n- Explicitly document all involved sites (bilateral ovaries/tubes, pelvic peritoneum, omentum, right paracolic gutter) and margin/residual disease status [@HISTOLOGY_AND_IHC.3|unknown].  \n- Perform detailed fallopian tube examination (SEE‑FIM) to assess for STIC and define primary site; currently unknown/needs update.  \n- Clearly distinguish ovarian carcinoma from separate right breast NST carcinoma with DCIS; cross‑reference both primaries in final summary [@HISTOLOGY_AND_IHC.5|unknown].  \n- Recommend germline/somatic BRCA1/2 and HRD/HRR testing on tubo‑ovarian carcinoma tissue; current molecular status unknown/needs update.&quot;,
    &quot;nuclear&quot;: &quot;- PET shows FDG‑avid pelvic mass with peritoneal disease, supporting advanced tubo‑ovarian carcinoma staging and baseline disease mapping [@IMAGING_CONTEXT|Unknown].  \n- FDG‑avid right breast lesion corresponds to known early breast primary; no additional hypermetabolic breast focus described [@IMAGING_CONTEXT|Unknown].  \n- Left breast BI‑RADS 3 lesion remains low suspicion; no PET-based upstaging, short-interval imaging follow-up appropriate [@IMAGING_CONTEXT|2024-06-05].  \n- Small lung nodules are indeterminate and non-dec definitive for metastasis on PET; require serial chest CT characterization [@IMAGING_CONTEXT|Unknown].  \n- Complete formal PET/CT report with SUVs, nodal/distant status, and postoperative imaging correlation is still needed to finalize FIGO stage (unknown/needs update).&quot;
  },
  &quot;Round 2&quot;: {
    &quot;chair&quot;: &quot;- Finalize staging: obtain integrated gyn-onc pathology with FIGO stage, STIC status, primary confirmation, and operative note including residual disease description (R0 vs residual) – all currently unknown.  \n- Complete baseline workup: postoperative pelvic CT/MRI, full PET/CT with SUVs and mapping, CA125 baseline/trend, labs, performance status, venous access – all unknown/needs update.  \n- Plan first-line ovarian systemic therapy with curative intent once staging and organ function are defined; preplan transition into biomarker‑guided maintenance.  \n- Expedite germline and somatic BRCA1/2 and HRD/HRR testing (MSI/TMB/PD‑L1 later if needed) for maintenance strategy and family counseling – all unknown.  \n- Coordinate breast and lung management: confirm final breast adjuvant plan and margins/nodes; arrange serial chest CT and left breast follow‑up imaging protocol – all unknown/needs update.&quot;,
    &quot;oncologist&quot;: &quot;- Plan first‑line adjuvant systemic therapy for high‑grade serous tubo‑ovarian carcinoma with curative intent; exact regimen pending staging/fitness (unknown/needs update).  \n\n- Obtain operative note, integrated gyn‑onc pathology assigning FIGO stage/STIC, and residual disease description to calibrate adjuvant intensity and maintenance (unknown/needs update).  \n\n- Update baseline CA125, CBC, renal/hepatic function, performance status, and venous access before initiating systemic treatment (unknown/needs update).  \n\n- Coordinate final adjuvant breast plan (endocrine ± radiation) and schedule around ovarian chemotherapy; confirm margins/nodes on synoptic report (unknown/needs update).  \n\n- Complete postoperative pelvic CT/MRI, serial chest CT, full PET/CT, and germline/somatic BRCA/HRD testing to refine staging and maintenance options (unknown/needs update).&quot;,
    &quot;radiologist&quot;: &quot;- Postoperative pelvic disease burden, residual peritoneal implants, and FIGO stage remain indeterminate on imaging; dedicated pelvic CT/MRI needed, currently unknown/needs update.  \n\n- Character, number, and growth of small lung nodules are not defined; serial chest CT with standardized protocol required, currently unknown/needs update.  \n\n- Extent and distribution of preoperative FDG-avid pelvic/peritoneal disease and nodal/distant involvement remain unclear without full PET/CT report, currently unknown/needs update.  \n\n- Right breast postoperative imaging baseline and correlation with prior FDG-avid lesion not documented; current status and surveillance plan unknown/needs update.  \n\n- Left breast BI-RADS 3 lesion requires protocolled short-interval ultrasound/mammographic follow-up; current interval imaging schedule unknown/needs update.&quot;,
    &quot;pathologist&quot;: &quot;- Issue integrated gyn-onc report consolidating all pelvic/peritoneal specimens, confirming single HGSC, primary site, and FIGO stage [@HISTOLOGY_AND_IHC.2|2024-06-17].  \n- Document all involved sites (bilateral ovaries/tubes, pelvic peritoneum, omentum, right paracolic gutter) and any macroscopic residual disease; margins currently unknown.  \n- Perform SEE-FIM on fallopian tubes; explicitly report STIC presence/absence to support tubo-ovarian primary assignment; status currently unknown.  \n- Provide synoptic right-breast report confirming tumor size, grade II, margins, and axillary nodes 0/3 pN0 [@HISTOLOGY_AND_IHC.5|unknown].  \n- Recommend germline and somatic BRCA1/2 and broader HRD/HRR testing for tubo-ovarian carcinoma; molecular status currently unknown.&quot;,
    &quot;nuclear&quot;: &quot;- PET shows FDG‑avid pelvic mass with peritoneal involvement, supporting advanced tubo‑ovarian carcinoma and guiding baseline disease mapping [@IMAGING_CONTEXT|Unknown].  \n- FDG‑avid right breast focus corresponds to known primary; no additional hypermetabolic breast lesions reported [@IMAGING_CONTEXT|Unknown].  \n- Left breast BI‑RADS 3 lesion remains low‑suspicion; PET does not upstage, needs short‑interval mammographic follow‑up [@IMAGING_CONTEXT|2024-06-05].  \n- Small lung nodules are PET‑indeterminate; they do not currently upstage but require serial chest CT characterization [@IMAGING_CONTEXT|Unknown].  \n- Full preoperative PET/CT report with SUVs and nodal/distant mapping remains outstanding and is critical to finalize staging (unknown/needs update).&quot;
  }
}</pre>
  </details>

  <details class="mt">
    <summary>Selected Clinical Context (JSON)</summary>
    <pre>{
  &quot;lab&quot;: {
    &quot;chair&quot;: [],
    &quot;oncologist&quot;: [],
    &quot;radiologist&quot;: [],
    &quot;pathologist&quot;: [],
    &quot;nuclear&quot;: []
  },
  &quot;imaging&quot;: {
    &quot;chair&quot;: [],
    &quot;oncologist&quot;: [],
    &quot;radiologist&quot;: [],
    &quot;pathologist&quot;: [],
    &quot;nuclear&quot;: []
  },
  &quot;pathology&quot;: {
    &quot;chair&quot;: [],
    &quot;oncologist&quot;: [],
    &quot;radiologist&quot;: [],
    &quot;pathologist&quot;: [],
    &quot;nuclear&quot;: []
  },
  &quot;mutation&quot;: {
    &quot;chair&quot;: [],
    &quot;oncologist&quot;: [],
    &quot;radiologist&quot;: [],
    &quot;pathologist&quot;: [],
    &quot;nuclear&quot;: []
  }
}</pre>
  </details>

  <details class="mt">
    <summary>Global Guideline RAG</summary>
    <h3>RAG Query</h3>
    <pre>High-grade serous carcinoma involving ovaries, tubes, pelvic peritoneum, omentum; platinum status unknown; no BRCA/HRD/MSI/PD-L1 data; concurrent ER/PR+ HER2- right breast cancer pT1cN0; need info on performance status, organ function, anemia, renal reserve.</pre>
    <h3>Evidence Pack (top-k)</h3>
    <pre>RAG Evidence Pack (top=5):
[1] score=0.6398 esgo_eshre_esge_fertilitysparing_pocket_2025__v00000000 [PAGE 17]
    to the use of ovarian preservation itself and/or the natural history of the disease (whatever the preservation or not of the ovary) in these patients having poorest prognostic factors). 1non-invasive peritoneal implants; 2including immature teratoma, dysgerminoma, Yolk-sac tumours; 3well and moderat…
[2] score=0.6354 nccn_ovariancancer_v3_2025__v00000000 [PAGE 14]
    ff Definitions of platinum-sensitive and platinum-resistant disease represent a spectrum of disease; clinical judgment and flexibility should be utilized in determining treatment options. gg Data are limited on primary and maintenance therapy for recurrent/ persistent LCOC. hh During and after treat…
[3] score=0.6300 esgo_esmo_esp_consensus_ovariancancer_2024__v00000000 [PAGE 6]
    carcinoma demonstrated that adjuvant platinum-based ChT prolonged survival, but did not prospectively evaluate his- tological subtypes.38,39 High-grade EC has a similar prog- nosis to HGSC and is worse than low-grade EC. It is not clear whether there is any survival beneﬁt for adjuvant ChT in stage …
[4] score=0.6219 esmo_cpg_epithelialovarian_2023__v00000000 [PAGE 10]
    with ﬁrst line. This can probably be explained by an accu- mulative exposure to platinum.85 Several factors need to be taken into consideration for the selection of PARPis or anti-VEGF therapies in relapse including histotype, BRCA1/2-mut status, prior therapies (PARPi and/or bevacizumab), expected …
[5] score=0.6180 nccn_ovariancancer_v3_2025__v00000000 [PAGE 15]
    based chemotherapy,n preferred for first recurrence (category 1) or Recurrence therapyn,kk and/or Best supportive care (See NCCN Guidelines for Palliative Care) Consider secondary cytoreductive surgeryj,k Immediate platinum-based recurrence therapyn (category 2B) and/or Best supportive care (See NCC…</pre>
    <h3>RAG Raw Hits (JSON)</h3>
    <pre>[
  {
    &quot;rank&quot;: 1,
    &quot;score&quot;: 0.6398075819015503,
    &quot;doc_id&quot;: &quot;esgo_eshre_esge_fertilitysparing_pocket_2025__v00000000&quot;,
    &quot;page&quot;: 17,
    &quot;text&quot;: &quot;to the use of ovarian preservation itself and/or the natural history of the disease (whatever\nthe preservation or not of the ovary) in these patients having poorest prognostic factors).\n1non-invasive peritoneal implants; 2including immature teratoma, dysgerminoma, Yolk-sac\ntumours; 3well and moderately differentiated; 4poorly differentiated; #for grade 2-3 imma-\nture teratoma stage II-IV, fertility-sparing data are limited; ## for Sertoli-Leydig cell tumour\nstage IC2-3, fertility-sparing data are limited.\nBOT borderline ovarian tumour; CCC clear cell carcinoma; GCT germ cell tumour; GrCT\ngranulosa cell tumour; HGEC high-grade endometrioid carcinoma; HGSC high-grade serous\ncarcinoma; LGSC low-grade serous carcinoma; LGEC low-grade endometrioid carcinoma,\nMCexp mucinous carcinoma with expansile invasion, MCinf mucinous carcinoma with in-\nfiltrative invasion; SCC small cell carcinoma; SLCT Sertoli-Leydig cell tumour.&quot;
  },
  {
    &quot;rank&quot;: 2,
    &quot;score&quot;: 0.6354184746742249,
    &quot;doc_id&quot;: &quot;nccn_ovariancancer_v3_2025__v00000000&quot;,
    &quot;page&quot;: 14,
    &quot;text&quot;: &quot;ff Definitions of platinum-sensitive and platinum-resistant disease\nrepresent a spectrum of disease; clinical judgment and flexibility should\nbe utilized in determining treatment options.\ngg Data are limited on primary and maintenance therapy for recurrent/\npersistent LCOC.\nhh During and after treatment for recurrence, patients should be evaluated\nas indicated with tumor markers and repeat imaging (with modalities\npreviously used) to document response and/or disease status.\nii Ancillary Palliative Surgical Procedures (OV-A 4 of 4).\njj Patients who do not respond and progress on two consecutive regimens\nwithout evidence of clinical benefits have diminished likelihood of\nbenefitting from additional therapy (Griffiths RW, et al. Int J Gynecol\nCancer 2011;21:58-65). Decisions to offer clinical trials, supportive care,\nor additional therapy should be made on an individual basis.\nkk Localized radiation therapy (RT) can be considered to palliate\nsymptoms and/or for oligometastatic disease.\nOV-8\nPLEASE NOTE that use of this NCCN Content is governed by the End-User License Agreement, and you MAY NOT distribute this Content or use it with any artificial intelligence model or tool.&quot;
  },
  {
    &quot;rank&quot;: 3,
    &quot;score&quot;: 0.6299822926521301,
    &quot;doc_id&quot;: &quot;esgo_esmo_esp_consensus_ovariancancer_2024__v00000000&quot;,
    &quot;page&quot;: 6,
    &quot;text&quot;: &quot;carcinoma demonstrated that adjuvant platinum-based ChT\nprolonged survival, but did not prospectively evaluate his-\ntological subtypes.38,39 High-grade EC has a similar prog-\nnosis to HGSC and is worse than low-grade EC. It is not clear\nwhether there is any survival beneﬁt for adjuvant ChT in\nstage IA or IB CCC.40,41\nRecommendation\n7.1:\nComplete\nsurgical\nresection\nincluding total abdominal hysterectomy, bilateral salpingo-\noophorectomy, omentectomy, systematic pelvic and para-\naortic lymph node dissection, peritoneal biopsies and\ncytological analysis should be the standard surgical pro-\ncedure in stage I-II high-grade EC, CCC and high-risk\nmucinous ovarian carcinoma [IV, A].\nConsensus: 97% (38) yes, 3% (1) no, 0% (0) abstain (39\nvoters)\nRecommendation 7.2: Patients with stage I-II high-grade\nEC should be offered adjuvant platinum-based ChT [IV, A].\nConsensus: 100% (39) yes, 0% (0) no, 0% (0) abstain (39\nvoters)\nRecommendation 7.3: Adjuvant ChT may be omitted for\nadequately staged IA or IB CCC [IV, C].\nConsensus: 90% (35) yes, 5% (2) no, 5% (2) abstain (39\nvoters)\nRecommendation 7.4: Adjuvant ChT may be considered\nfor stage IC1 CCC [IV, C].&quot;
  },
  {
    &quot;rank&quot;: 4,
    &quot;score&quot;: 0.6218518018722534,
    &quot;doc_id&quot;: &quot;esmo_cpg_epithelialovarian_2023__v00000000&quot;,
    &quot;page&quot;: 10,
    &quot;text&quot;: &quot;with ﬁrst line. This can probably be explained by an accu-\nmulative exposure to platinum.85\nSeveral factors need to be taken into consideration for\nthe selection of PARPis or anti-VEGF therapies in relapse\nincluding histotype, BRCA1/2-mut status, prior therapies\n(PARPi and/or bevacizumab), expected response to plat-\ninum ChT, presence of symptoms (speciﬁcally ascites),\npersistent toxicities from prior therapies, no contraindica-\ntion to bevacizumab and patient preference. Generally, for\nsymptomatic patients requiring a rapid treatment response,\nthe combination of carboplatin with bevacizumab would be\nrecommended (Figure 3).\nFurther information is provided in the Supplementary\nMaterial Section 4, available at https://doi.org/10.1016/j.\nannonc.2023.07.011.\nSystemic therapy when platinum is not an option\nFor some patients with recurrent ovarian cancer, platinum\nrechallenge may not be considered clinically appropriate.\nFor these patients, alternative systemic treatments are\navailable. Patients with good performance status should be\nprioritised for novel therapies within clinical trials. Inte-\ngrating early palliative care is particularly crucial.&quot;
  },
  {
    &quot;rank&quot;: 5,
    &quot;score&quot;: 0.6179865002632141,
    &quot;doc_id&quot;: &quot;nccn_ovariancancer_v3_2025__v00000000&quot;,
    &quot;page&quot;: 15,
    &quot;text&quot;: &quot;based chemotherapy,n\npreferred for first\nrecurrence (category 1)\nor\nRecurrence therapyn,kk\nand/or\nBest supportive care\n(See NCCN Guidelines\nfor Palliative Care)\nConsider\nsecondary\ncytoreductive\nsurgeryj,k\nImmediate platinum-based\nrecurrence therapyn (category 2B)\nand/or\nBest supportive care (See NCCN\nGuidelines for Palliative Care)\nRECURRENCE THERAPY FOR PLATINUM-SENSITIVE DISEASEn,gg,hh,ii\nMaintenance therapy (if PR or CR)\n• Useful in certain circumstances:\n\u0017Continue bevacizumab if previously\ntreated with chemotherapy +\nbevacizumab;\nor\n\u0017PARPi therapy (for those with BRCA\n1/2 mutation)ll:\n ◊If not previously used (category 1)\n ◊If disease has not progressed\nduring prior PARPi treatment\nor\nObserve\ngg Data are limited on primary and maintenance therapy for recurrent/persistent LCOC.\nhh During and after treatment for recurrence, patients should be evaluated as indicated with\ntumor markers and repeat imaging (with modalities previously used) to document response\nand/or disease status.\nii Ancillary Palliative Surgical Procedures (OV-A 4 of 4).\nkk Localized RT can be considered to palliate symptoms and/or for oligometastatic disease.&quot;
  }
]</pre>
    <h3>Digest (<=8 bullets)</h3>
    <pre>- In early-stage epithelial ovarian cancer, high‑grade endometrioid carcinoma has prognosis similar to high‑grade serous; adjuvant platinum‑based chemotherapy improves survival overall, but a clear survival benefit for adjuvant chemotherapy in stage IA/IB low‑grade endometrioid or clear‑cell carcinoma has not been demonstrated and should be individualized [esgo_esmo_esp_consensus_ovariancancer_2024__v00000000].  
- For recurrent ovarian cancer, “platinum‑sensitive” vs “platinum‑resistant” represents a continuum; NCCN recommends using clinical judgment and flexibility (prior therapies, interval from last platinum, toxicity, patient status) when deciding systemic therapy and trial options [nccn_ovariancancer_v3_2025__v00000000].  
- At first recurrence after platinum‑sensitive disease, platinum‑based combination chemotherapy is preferred (category 1) and may be combined with maintenance strategies; consider secondary cytoreductive surgery in appropriately selected patients and always integrate best supportive care as needed [nccn_ovariancancer_v3_2025__v00000000].  
- In relapsed disease, selection between PARP inhibitors and anti‑VEGF therapy should account for histologic subtype, BRCA1/2 status, prior PARP/anti‑VEGF exposure, expected toxicities, treatment goals, and patient preference; cumulative prior platinum exposure influences benefit and toxicity profiles [esmo_cpg_epithelialovarian_2023__v00000000].  
- Data on primary and maintenance therapy for recurrent/persistent low‑grade or clear‑cell ovarian carcinoma are limited; individualized treatment decisions and clinical trial participation are encouraged [nccn_ovariancancer_v3_2025__v00000000].  
- For malignant ovarian germ‑cell tumors (e.g., immature teratoma, dysgerminoma, yolk‑sac tumors) and select borderline tumors, fertility‑sparing surgery with ovarian preservation is generally acceptable when complete staging and appropriate adjuvant therapy are provided; prognosis is often favorable, supporting conservative approaches in suitable candidates [esgo_eshre_esge_fertilitysparing_pocket_2025__v00000000].  
- Ovarian preservation decisions must consider tumor type, stage, and prognostic factors; in borderline tumors with non‑invasive peritoneal implants, fertility‑sparing options are possible but require careful counseling on recurrence risk and long‑term surveillance [esgo_eshre_esge_fertilitysparing_pocket_2025__v00000000].</pre>
  </details>

  <details class='mt' open><summary>Pipeline Flow (Mermaid)</summary><pre class='mermaid'>flowchart TD
  A[Load Case + Fingerprint] --&gt; B[Load Reports]
  B --&gt; C[Report Selection per Role]
  C --&gt; D[Global Guideline RAG]
  D --&gt; E[Init Specialist Agents]
  E --&gt; F[MDT Discussion Engine]
  F --&gt; G[Trial Matching]
  G --&gt; H[Final Chair Output]
  H --&gt; I[Save Logs]
</pre></details>

  <details class="mt">
    <summary>Trace Events (JSON)</summary>
    <pre>[
  {
    &quot;ts&quot;: &quot;2026-01-18T01:01:39.177788&quot;,
    &quot;event&quot;: &quot;pipeline_start&quot;,
    &quot;payload&quot;: {
      &quot;visit_time&quot;: &quot;2024-07-17 15:38:50.183000&quot;,
      &quot;meta_info&quot;: &quot;23080319700310062X&quot;
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-18T01:01:39.178793&quot;,
    &quot;event&quot;: &quot;case_fingerprint&quot;,
    &quot;payload&quot;: {
      &quot;case_fingerprint&quot;: &quot;3e5e8991197e&quot;
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-18T01:01:39.475946&quot;,
    &quot;event&quot;: &quot;reports_loaded&quot;,
    &quot;payload&quot;: {
      &quot;lab_n&quot;: 0,
      &quot;img_n&quot;: 0,
      &quot;path_n&quot;: 0,
      &quot;mut_n&quot;: 0,
      &quot;cutoff_dt&quot;: &quot;2024-07-18 15:38:50&quot;
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-18T01:01:39.540101&quot;,
    &quot;event&quot;: &quot;reports_selected&quot;,
    &quot;payload&quot;: {
      &quot;lab&quot;: {
        &quot;chair&quot;: [],
        &quot;oncologist&quot;: [],
        &quot;radiologist&quot;: [],
        &quot;pathologist&quot;: [],
        &quot;nuclear&quot;: []
      },
      &quot;imaging&quot;: {
        &quot;chair&quot;: [],
        &quot;oncologist&quot;: [],
        &quot;radiologist&quot;: [],
        &quot;pathologist&quot;: [],
        &quot;nuclear&quot;: []
      },
      &quot;pathology&quot;: {
        &quot;chair&quot;: [],
        &quot;oncologist&quot;: [],
        &quot;radiologist&quot;: [],
        &quot;pathologist&quot;: [],
        &quot;nuclear&quot;: []
      },
      &quot;mutation&quot;: {
        &quot;chair&quot;: [],
        &quot;oncologist&quot;: [],
        &quot;radiologist&quot;: [],
        &quot;pathologist&quot;: [],
        &quot;nuclear&quot;: []
      }
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-18T01:02:05.567893&quot;,
    &quot;event&quot;: &quot;rag_query&quot;,
    &quot;payload&quot;: {
      &quot;query&quot;: &quot;High-grade serous carcinoma involving ovaries, tubes, pelvic peritoneum, omentum; platinum status unknown; no BRCA/HRD/MSI/PD-L1 data; concurrent ER/PR+ HER2- right breast cancer pT1cN0; need info on performance status, organ function, anemia, renal reserve.&quot;
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-18T01:02:05.567902&quot;,
    &quot;event&quot;: &quot;rag_hits&quot;,
    &quot;payload&quot;: {
      &quot;topk&quot;: 5,
      &quot;n&quot;: 5
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-18T01:02:14.294100&quot;,
    &quot;event&quot;: &quot;mdt_discussion_start&quot;,
    &quot;payload&quot;: {
      &quot;num_rounds&quot;: 2,
      &quot;num_turns&quot;: 2
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-18T01:06:16.182672&quot;,
    &quot;event&quot;: &quot;mdt_discussion_end&quot;,
    &quot;payload&quot;: {
      &quot;merged_chars&quot;: 4506
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-18T01:06:16.183310&quot;,
    &quot;event&quot;: &quot;final_output_start&quot;,
    &quot;payload&quot;: {}
  },
  {
    &quot;ts&quot;: &quot;2026-01-18T01:06:20.262233&quot;,
    &quot;event&quot;: &quot;final_output_end&quot;,
    &quot;payload&quot;: {
      &quot;final_output_chars&quot;: 1751
    }
  }
]</pre>
  </details>

</body>
</html>
